Compare ALEMBIC LTD with Aventis Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC LTD vs SANOFI INDIA - Comparison Results

ALEMBIC LTD     Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC LTD SANOFI INDIA ALEMBIC LTD/
SANOFI INDIA
 
P/E (TTM) x 46.5 38.7 119.9% View Chart
P/BV x 1.9 6.9 27.4% View Chart
Dividend Yield % 0.5 1.3 42.6%  

Financials

 ALEMBIC LTD   SANOFI INDIA
EQUITY SHARE DATA
    ALEMBIC LTD
Mar-18
SANOFI INDIA
Dec-18
ALEMBIC LTD/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs726,840 1.1%   
Low Rs344,630 0.7%   
Sales per share (Unadj.) Rs4.71,203.1 0.4%  
Earnings per share (Unadj.) Rs6.1165.3 3.7%  
Cash flow per share (Unadj.) Rs6.2209.9 3.0%  
Dividends per share (Unadj.) Rs0.2084.00 0.2%  
Dividend yield (eoy) %0.41.5 25.8%  
Book value per share (Unadj.) Rs40.7963.6 4.2%  
Shares outstanding (eoy) m267.0323.03 1,159.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x11.34.8 236.3%   
Avg P/E ratio x8.734.7 25.0%  
P/CF ratio (eoy) x8.527.3 31.0%  
Price / Book Value ratio x1.36.0 21.9%  
Dividend payout %3.350.8 6.4%   
Avg Mkt Cap Rs m14,139132,078 10.7%   
No. of employees `000NA3.3 0.0%   
Total wages/salary Rs m2074,068 5.1%   
Avg. sales/employee Rs ThNM8,393.8-  
Avg. wages/employee Rs ThNM1,232.4-  
Avg. net profit/employee Rs ThNM1,153.0-  
INCOME DATA
Net Sales Rs m1,25527,708 4.5%  
Other income Rs m370897 41.3%   
Total revenues Rs m1,62528,605 5.7%   
Gross profit Rs m1116,235 1.8%  
Depreciation Rs m381,027 3.7%   
Interest Rs m27 24.3%   
Profit before tax Rs m4426,098 7.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m1,2120-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m242,292 1.0%   
Profit after tax Rs m1,6303,806 42.8%  
Gross profit margin %8.922.5 39.3%  
Effective tax rate %5.437.6 14.4%   
Net profit margin %129.813.7 945.3%  
BALANCE SHEET DATA
Current assets Rs m1,86715,922 11.7%   
Current liabilities Rs m5916,235 9.5%   
Net working cap to sales %101.635.0 290.7%  
Current ratio x3.22.6 123.7%  
Inventory Days Days9464 148.1%  
Debtors Days Days7421 352.4%  
Net fixed assets Rs m1,7917,539 23.8%   
Share capital Rs m534230 232.2%   
"Free" reserves Rs m10,32421,962 47.0%   
Net worth Rs m10,85822,192 48.9%   
Long term debt Rs m410-   
Total assets Rs m11,59129,839 38.8%  
Interest coverage x260.9872.1 29.9%   
Debt to equity ratio x00-  
Sales to assets ratio x0.10.9 11.7%   
Return on assets %14.112.8 110.2%  
Return on equity %15.017.2 87.5%  
Return on capital %15.227.5 55.2%  
Exports to sales %1.50-   
Imports to sales %21.00-   
Exports (fob) Rs m19NA-   
Imports (cif) Rs m263NA-   
Fx inflow Rs m197,587 0.3%   
Fx outflow Rs m2647,145 3.7%   
Net fx Rs m-244442 -55.3%   
CASH FLOW
From Operations Rs m2363,739 6.3%  
From Investments Rs m-224-731 30.6%  
From Financial Activity Rs m-27-1,972 1.3%  
Net Cashflow Rs m-151,036 -1.4%  

Share Holding

Indian Promoters % 64.0 0.0 -  
Foreign collaborators % 0.0 60.4 -  
Indian inst/Mut Fund % 0.2 14.4 1.4%  
FIIs % 9.7 14.6 66.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.1 10.5 248.6%  
Shareholders   54,701 15,184 360.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC LTD With:   SUN PHARMA  DR. REDDYS LAB  ABBOTT INDIA  FULFORD INDIA  PROCTER & GAMBLE HEALTH  

Compare ALEMBIC LTD With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 674 Points Lower; Banking and Finance Stocks Witness Selling(Closing)

Indian share markets witnessed selling pressure throughout the day and ended lower. Investors were worried about the economic impact and uncertainty over the coronavirus pandemic.

Related Views on News

ALEMBIC LTD Announces Quarterly Results (1QFY20); Net Profit Down 70.9% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, ALEMBIC LTD has posted a net profit of Rs 20 m (down 70.9% YoY). Sales on the other hand came in at Rs 260 m (down 41.5% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY20); Net Profit Down 2.2% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, SANOFI INDIA has posted a net profit of Rs 974 m (down 2.2% YoY). Sales on the other hand came in at Rs 7 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

ALEMBIC LTD Announces Quarterly Results (4QFY19); Net Profit Down 14.6% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, ALEMBIC LTD has posted a net profit of Rs 40 m (down 14.6% YoY). Sales on the other hand came in at Rs 253 m (down 23.8% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

SANOFI INDIA Announces Quarterly Results (4QFY19); Net Profit Up 12.6% (Quarterly Result Update)

May 8, 2019 | Updated on May 8, 2019

For the quarter ended March 2019, SANOFI INDIA has posted a net profit of Rs 929 m (up 12.6% YoY). Sales on the other hand came in at Rs 7 bn (up 16.1% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA 2017-18 Annual Report Analysis (Annual Result Update)

Apr 16, 2019 | Updated on Apr 16, 2019

Here's an analysis of the annual report of SANOFI INDIA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SANOFI INDIA. Also includes updates on the valuation of SANOFI INDIA.

More Views on News

Most Popular

Sorry Warren Buffett, I'm Following This Man Instead of You in 2020(The 5 Minute Wrapup)

Mar 30, 2020

This man warned of an impending market correction while everyone else was celebrating the renewed optimism in early 2020...

The Biggest Trading Opportunity of 2020 is Here...

Mar 26, 2020

India's #1 trader, Vijay Bhambwani, talks about a hugely profitable trading opportunity which you must know about today!

A Big Trading Opportunity is Coming Your Way Soon(Fast Profits Daily)

Mar 25, 2020

I see a big opportunity to make fast profits on the horizon.

Coronavirus Sell-off Is a Perfect Time to 'Lockdown' this 'Crorepati' Stock(Profit Hunter)

Mar 24, 2020

Coronavirus crisis and panic selling has brought this quality smallcap to multiyear lows, making it a great bargain.

Lockdown! Now the Bailout...(The Honest Truth)

Mar 25, 2020

Ajit Dayal on what India should do to manage the coronavirus impact on the economy.

More

How to Trade the
Coronavirus Crash

Coronavirus Crash
Get this special report, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

ALEMBIC LTD SHARE PRICE


Apr 3, 2020 (Close)

TRACK ALEMBIC LTD

  • Track your investment in ALEMBIC LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ALEMBIC LTD 8-QTR ANALYSIS

COMPARE ALEMBIC LTD WITH

MARKET STATS